West-Ward Pharmaceuticals now Hikma in the US as part of global rebranding

Eatontown, NJ, June 26, 2018 - Hikma Pharmaceuticals PLC (the Hikma Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the multinational generic pharmaceutical company, announced today that its wholly-owned US subsidiary, West-Ward Pharmaceuticals Corp., will now operate as Hikma Pharmaceuticals USA Inc. or simply “Hikma.”

Press Release Corporate 26 June 2018

text

The Hikma Group acquired West-Ward Pharmaceuticals Corp. more than 20 years ago and since then it has become a leading provider of quality oral, liquid, inhalant, and injectable branded and non-branded generic medicines in the US.

The name change is part of the Hikma Group’s global rebranding effort that is bringing all its subsidiary corporate brands under a refreshed Hikma Group brand, which includes a new positioning and visual identity. The new brand emphasizes the Hikma Group’s role in improving the health of people around the world by making quality medicines and making them affordable and accessible. The unveiling marks the Hikma Group’s 40th anniversary and the beginning of a new chapter in the company’s history. Other US subsidiaries will also have similar name changes to align with the new Hikma brand.

“This is a really important turning point for our more than 2,000 US based employees,” explained Brian Hoffmann, President of the US Generics Business. “In an increasingly global world, it is important that our employees, as well as our customers and partners, can benefit from the synergies and efficiencies of Hikma operating all operations under one brand. While our US name is changing, our commitment to our state-of–the-art US manufacturing, robust R&D investments and the US market overall remains as strong as ever.”

Dan Motto, Executive Vice President, Commercial Development Strategy for the US Injectables Business added, “For our US customers and partners the transition to Hikma will be seamless with no change to our strong portfolio of products or our ongoing commitment to deliver great customer service and our dedication to patients. Beginning today, most touchpoints in the US will now bear the new Hikma logo including our building signage, our company collateral, and our website. Our updated product packaging and labelling will be rolled out over the next 12 to18 months, with our priority being to maintain consistent supply and patient safety.”

The Hikma Group’s CEO, Siggi Olafsson added, “We believe that operating all our companies as Hikma in our markets will allow us to better serve customers, be more efficient, and to build on the trusted Hikma name. We want to draw on the strengths we have around the world and unlock the power of a single, global brand.”

The new logo is a wordmark with the name of the company in precisely drawn and spaced lettering, punctuated at the end with a full stop that conveys certainty and confidence, as well as a nod to the digital age. The coral color is connected to the legacy red of the original Hikma Group logo but re-interpreted in a contemporary hue. The simple style and lower-case letters make the brand friendly and approachable.

The US brand launch this week coincides with the European launch, and means that the new logo and new design system are now live across mobile, social and web properties in all of the Hikma Group’s markets.

For more information about our US business, please visit www.hikma.com/us 

Important notice for users

You are about to access Hikma historic archive material. Any reference in these archives to Hikma products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data, or safety data. Please refer to your approved national product label (SmPC) for current product information.

I have read this warning and will not be using any of the contained product information for clinical purposes.